Showing results (1-10 of 103) with videos related to
Sort By:
Pageof 11
Comparative Medicine|July 1, 2008
A structured light-based system for scanning subcutaneous tumors in laboratory animalsIbrahim Cem Girit, Maria Jure-Kunkel, Kim W McIntyreClinical Immunology (Orlando, Fla.)|August 21, 2007
Established B16 tumors are rejected following treatment with GM-CSF-secreting tumor cell immunotherapy in combination with anti-4-1BB mAbBetty Li, Jianmin Lin, Melinda Vanroey, et al.Cancer Immunology, Immunotherapy : CII|July 23, 2013
Synergy between chemotherapeutic agents and CTLA-4 blockade in preclinical tumor modelsMaria Jure-Kunkel, Gregg Masters, Emel Girit, et al.Seminars in Oncology|August 31, 2015
Agonists of Co-stimulation in Cancer Immunotherapy Directed Against CD137, OX40, GITR, CD27, CD28, and ICOSMiguel F Sanmamed, Fernando Pastor, Alfonso Rodriguez, et al.Journal of Translational Medicine|March 26, 2013
Gene expression profiling of whole blood in ipilimumab-treated patients for identification of potential biomarkers of immune-related gastrointestinal adverse eventsVafa Shahabi, David Berman, Scott D Chasalow, et al.Head & Neck|December 9, 2014
Multimodal imaging analysis of an orthotopic head and neck cancer mouse model and application of anti-CD137 tumor immune therapyAnne-Kristin Vahle, Sven Hermann, Michael Schäfers, et al.Radiation Research|March 26, 2010
Radiotherapy enhances antitumor effect of anti-CD137 therapy in a mouse Glioma modelElizabeth W Newcomb, Yevgeniy Lukyanov, Noriko Kawashima, et al.Cancer Research|August 25, 2018
Inhibition of Casein Kinase 2 Disrupts Differentiation of Myeloid Cells in Cancer and Enhances the Efficacy of Immunotherapy in MiceAyumi Hashimoto, Chan Gao, Jerome Mastio, et al.European Journal of Immunology|January 17, 2016
Deciphering CD137 (4-1BB) signaling in T-cell costimulation for translation into successful cancer immunotherapyAlfonso R Sanchez-Paulete, Sara Labiano, Maria E Rodriguez-Ruiz, et al.Cancer Immunology, Immunotherapy : CII|December 8, 2011
An immune-active tumor microenvironment favors clinical response to ipilimumabRui-Ru Ji, Scott D Chasalow, Lisu Wang, et al.Pageof 11